VANCOUVER, May 20 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in
the development of receptor targeted fusion proteins, today announced that
preliminary data from the Phase 1 clinical study of PRX302 in patients with
moderate to severe benign prostatic hyperplasia (BPH), will be presented at
the 2008 Annual Meeting of the American Urological Association (AUA). The 2008
AUA Meeting is the world's largest gathering of urology professionals and will
take place at the Orange County Convention Center in Orlando, Florida.
